Cargando…

Salvage therapy of osimertinib plus anlotinib in advanced lung adenocarcinoma with leptomeningeal metastasis: A case report

Leptomeningeal metastasis (LM) is one of the most serious complications of advanced non-small cell lung cancer (NSCLC) and lacks standard treatment. Patients with LM often have a poor prognosis. Here, we report a 51-year-old man diagnosed as advanced lung adenocarcinoma and gene sequencing indicated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Kai, Fu, Yifan, Gao, Ziyuan, Jiang, Junhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189884/ https://www.ncbi.nlm.nih.gov/pubmed/35707406 http://dx.doi.org/10.1016/j.rmcr.2022.101682

Ejemplares similares

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
por: Wang, Mingzhao, et al.
Publicado: (2023)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
por: Yi, Yali, et al.
Publicado: (2022)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019)

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
por: Sakai, Hitomi, et al.
Publicado: (2017)

Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma
por: Gao, Zhiqiang, et al.
Publicado: (2020)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib
por: Wang, Yun, et al.
Publicado: (2023)

Identification of Cerebrospinal Fluid MicroRNAs Associated With Leptomeningeal Metastasis From Lung Adenocarcinoma
por: Pan, Zhenyu, et al.
Publicado: (2020)

CEACAM6 serves as a biomarker for leptomeningeal metastasis in lung adenocarcinoma
por: Wang, Xueying, et al.
Publicado: (2022)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study
por: Wang, Xia, et al.
Publicado: (2021)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer
por: Wang, Hai-ying, et al.
Publicado: (2020)

A Rare Case of Metastasis of Gastric Adenocarcinoma to the Leptomeninges
por: Doshi, Krishna, et al.
Publicado: (2023)

Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
por: Fu, Yang, et al.
Publicado: (2022)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature
por: Liu, Lei, et al.
Publicado: (2020)

Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report
por: Wang, Yunmei, et al.
Publicado: (2018)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling
por: Qin, Tingting, et al.
Publicado: (2020)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Triple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A case report
por: Hu, Xu-Yan, et al.
Publicado: (2021)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021)

AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
por: Wang, Chang-Lu, et al.
Publicado: (2022)

The efficacy and safety of anlotinib treatment for advanced lung cancer
por: Shao, Lan, et al.
Publicado: (2019)

A case report of prostate adenocarcinoma with leptomeningeal carcinomatosis and intracerebral metastasis
por: Fazilat‐Panah, Danial, et al.
Publicado: (2021)

Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
por: Yi, Yali, et al.
Publicado: (2022)

Unusual magnetic resonance imaging findings of brain and leptomeningeal metastasis in lung adenocarcinoma: A case report
por: Li, Na, et al.
Publicado: (2022)

Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR‐mutation non‐small cell lung cancer: A phase II single‐arm prospective clinical trial
por: Lu, Zhi‐qin, et al.
Publicado: (2020)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
por: Chen, Xuesong, et al.
Publicado: (2023)

Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases
por: Takeda, Takayuki, et al.
Publicado: (2017)

Ovarian Adenocarcinoma With Leptomeningeal Metastases
por: Bayas, Angel, et al.
Publicado: (2022)

Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism
por: Shen, Juan, et al.
Publicado: (2022)

Systematic Immunological Level Determined the Prognosis of Leptomeningeal Metastasis in Lung Cancer
por: Hong, Ye, et al.
Publicado: (2022)

Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for leptomeningeal metastasis and successful treatment with osimertinib: A case report and literature review
por: Sakurai, Takeo, et al.
Publicado: (2020)

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
por: Nanjo, Shigeki, et al.
Publicado: (2018)

Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
por: Li, Huiying, et al.
Publicado: (2019)

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
por: Wen, Lei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rbbjnm4m6h295cllgqvgthvand